IOVANCE BIOTHERAPEUTICS, INC. Accrued Employee Benefits, Current
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Accrued Employee Benefits, Current of $30.69 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedEmployeeBenefitsCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Employee Benefits, Current $30.69M.
- 2026-03-31: Accrued Employee Benefits, Current $28.17M.
- 2025-12-31: Accrued Employee Benefits, Current $33.78M.
- 2025-09-30: Accrued Employee Benefits, Current $28.14M.
| Period end | Accrued Employee Benefits, Current | Accrued Employee Benefits, Current as first filed |
|---|---|---|
| 2026-06-30 | $30.69M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $28.17M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $33.78M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $28.14M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $24.30M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $26.37M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $31.91M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $32.24M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $24.98M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $21.36M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $34.81M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $28.82M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $18.36M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $13.90M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $20.19M 10-K · filed 2024-02-28 | $19.41M 10-K · filed 2023-02-28 |
| 2022-09-30 | $19.17M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $13.47M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $18.20M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $21.51M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $15.17M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $10.21M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $7.90M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $9.03M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $7.87M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $7.11M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $4.12M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $6.87M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $5.22M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $3.94M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $2.23M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $4.11M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $2.90M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.61M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $1.66M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $2.61M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $1.56M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $1.63M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $1.05M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $1.58M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $31.00K 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |